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Abstract
Background:  The present report describes the outcomes of a co-
hort of patients with Candida induced septic shock.
Methods:  Retrospective analysis of individuals who had at least 
one positive blood culture for Candida species ≥ 48 h after ICU 
admission. Data from patients that developed septic shock within 
48 hr of the positive blood culture were compared to non-shock 
candidemic patients. Patients with a concomitant bacteremia and/or 
endocarditis were excluded.
Results:  Fifteen patients with Candida induced septic shock were 
studied and compared to 35 candidemic patients without shock. 
Overall mortality was 76% (87 % among those who had shock). A 
high proportion of non-albicans Candida species causing fungemia 
(74%) was observed. All patients with shock were receiving anti-
biotics but not antifungal treatment at the time of shock develop-
ment, eight were on parenteral nutrition, six on steroids and nine 
had a cancer history. High dose ﬂ  uconazole was the most common 
initial treatment provided. Four patients died before receiving any 
antifungal treatment. Time in ICU before the development of can-
didemia was identiﬁ  ed as a predictor of shock development (higher 
chance if fungemia developed < 7 days after ICU admission).
Conclusions:  Septic shock due to invasive candidiasis is a near fa-
tal condition. No conventional risk factors were identiﬁ  ed to predict 
shock development other than time (shorter) spent in ICU before 
the development of candidemia. We encourage clinicians to con-
sider the initiation of appropriate empiric antifungal treatment in 
high-risk patients who develop septic shock while on antimicrobial 
treatment.
Keywords:  Septic shock; Candidemia; Outcome; Predictor
Introduction
Candida is an increasing cause of bloodstream infection, 
causing signiﬁ  cant mortality and morbidity. Its overall in-
cidence rose ﬁ  vefold in the past ten years and remains the 
fourth leading cause of nosocomial bloodstream infection in 
the United States, accounting for 8% of all bloodstream in-
fections acquired in hospitals [1-3]. Furthermore, a change 
in the epidemiology has also been noted. Species other than 
C albicans have increased and surpassed C albicans in in-
cidence in some tertiary care centers [4-7]. Some of these 
emerging species have been correlated with increased viru-
lence [8], and in some reports with increased mortality [9]. 
Despite the availability of effective antifungal therapy, crude 
mortality in the last decade has remained high, ranging from 
36 to 90% [9-11].
A number of predisposing factors have been associated 
with development of invasive candidiasis and clinical 
predictors of poor outcome have been reported [12-14]. 
Nevertheless, studies describing the clinical course of patients 
developing candidemia are scant [15], and limited data exist 
of the outcomes of patients who develop septic shock due to 
invasive candidiasis [16]. In general, when patients develop 
septic shock, bacterial causes are exclusively considered and 
no effort to empirically treat Candida species is made.
The present report describes a cohort of patients with 
Candida induced septic shock. In order to identify predictors 
of shock development, data obtained from patients in shock 
were compared to a group of patients who had ICU acquired 
candidemia without shock.
Materials and Methods
The Human Investigation Committee (HIC) of Wayne State 
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University approved the study protocol. The medical records 
of patients who had at least one positive blood culture speci-
men of Candida spp. collected after their ICU admission 
at Harper University Hospital over a ﬁ  ve year span (1998 - 
2003) were reviewed. Case patients were deﬁ  ned as individ-
uals who had at least one positive blood culture for Candida 
species grown ≥ 48 h after ICU admission and in whom sep-
tic shock developed within 48 hrs of a positive blood culture. 
Patients who had a blood culture positive for a concomitant 
bacterial pathogen (i.e., mixed infection) and patients with 
endocarditis were excluded.
Deﬁ  nitions
Septic shock: acute circulatory failure characterized by per-
sistent arterial hypotension (systolic arterial pressure below 
90 mm Hg, a MAP < 60 mm Hg, or a reduction in systolic 
blood pressure of > 40 mm Hg from baseline, despite ad-
equate volume resuscitation, or the need for vasopressors 
in the absence of other causes for hypotension) in the pres-
ence of candidemia [17]. ICU acquired candidemia: Positive 
blood culture for Candida spp. grown ≥ 48 hrs after ICU 
admission. Colonization was deﬁ  ned as presence of Candida 
spp. in a non-sterile site. Candiduria as the presence of ≥ 104 
cfu/mL of Candida spp. in urine. Airway colonization: Can-
dida spp. isolated from tracheal aspirates or bronchoalveolar 
lavage specimens. Catheter-associated candidemia was de-
termined as ≥15 cfu of Candida spp. isolated from a central 
venous catheter tip.
Study variables
Study population characteristics and data extracted included 
demographics, age, and sex of the patients, reason for ICU 
admission, APACHE (Acute Physiology and Chronic Health 
Evaluation) II score at admission, length of stay (LOS) in 
ICU, hospital LOS, LOS prior to ICU admission, time in 
ICU before development of candidemia, predisposing risk 
factors for candidemia such as diabetes mellitus, broad spec-
trum antibiotic treatment (for > 3 days) during the hospital 
stay, chronic renal failure, liver disease, Candida coloniza-
tion, systematic administration of glucocorticosteroids for 
any reason in the last 30 days before ICU admission (regard-
less of dose), total parenteral nutrition administration, cen-
tral venous catheter (CVC) placement (for > 2 days), the day 
of candidemia occurrence, and outcome (i.e., dead or alive at 
ICU discharge).
Statistical analysis
The [chi]2 test or Fisher’s exact test was used to evaluate 
categorical variables and the Student’s t-test to evaluate con-
tinuous variables. Multiple logistic regression analysis was 
performed to identify independent variables associated with 
Figure 1. Flowchart of study subjects.
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development of shock. Potential risk factors were included 
in the analysis if they were associated with the dependent 
variables in the univariate analyses at a statistical level P < 
0.2. A P < 0.05 was considered statistically signiﬁ  cant in the 
multivariable models to show association between various 
potential risk factors and the dependent variable. An em-
pirical receiver operating curve (ROC) was created for each 
predictor. Also, sensitivity and speciﬁ  city for each predictor 
were calculated. The optimal threshold was chosen in such 
a way that the threshold made the resulting binary predic-
tion as close to the perfect operating point as possible. The 
Euclidean method was used to measure the distance between 
an observed point on the ROC curve and the perfect point.
Results
Fifteen patients with Candida induced septic shock were 
identiﬁ  ed and included in the study. Data obtained from this 
group was then compared to thirty-ﬁ  ve patients with ICU ac-
quired candidemia who did not develop shock (Fig. 1). The 
main characteristics of patients who developed shock are 
shown in Table 1. Patients with shock had higher illness acu-
ity, most had a history of cancer (60%) and four were neutro-
penic at the time of ICU admission. Candidemia in patients 
with shock developed 5.5 ± 3.8 days after ICU admission; 
only three patients had a positive blood culture within 48 hrs 
of ICU admission. Mortality among patients with Candida 
induced septic shock was 87%. All patients were receiving 
antibiotic treatment (mean number of antibiotic agents 4.1 
± 1.7) for 4.2 ± 3.9 days prior to the development of can-
didemia. Six (40%) patients were on corticosteroids (mean 
duration of treatment prior to candidemia 4.9 ± 2.6 days) 
and eight (53%) were on parenteral alimentation at the time 
of development of candidemia. All patients had at least one 
CVC in place. Ten patients were initially treated with high 
dose ﬂ  uconazole (≥ 12 mg/kg/day), one with amphotericin 
B, and four patients died before they received any antifungal 
treatment (culture results positive post mortem). Eight of the 
eleven treated patients cleared the fungemia after 7.4 ± 7.9 
days of antifungal treatment, and 3 patients had persistent 
candidemia. Antifungal therapy was subsequently changed 
in 6 patients (ﬁ  ve placed on deoxycholate amphotericin B 
and 1 on voriconazole).
Table 2 shows data for the whole cohort and compares 
candidemic patients with and without shock. Overall 
mortality was very high (76%). Patients in shock had a 
higher illness acuity and higher mortality. ICU stay prior 
to the development of candidemia was shorter in patients 
who developed shock and so was their overall hospital LOS 
(presumably because these patients died more rapidly). 
Duration of candidemia was identical in both groups. 
Although there were proportionally more patients with 
Candida albicans who developed shock, no signiﬁ  cant 
statistical difference in species was noted between the 
two groups. Four patients in the shock group (27%) had 
documented  Candida colonization (three patients had 
combined urine and sputum, one patient had only sputum 
Table 2. Patient Age, Acuity, Outcomes and Lengths of Stay
LOS: Length of stay
All Candidemias
(n = 50)
No shock
(n = 35)
Shock
(n = 15)
P Value
Age (years) 61 ± 14 60 ± 14 62 ± 13 0.64
Apache II 22.6 ± 8.3 21.1 ± 7.2 26.5 ± 9.7 0.04
Mortality (%) 76 71 87 0.30
Hospital LOS (days) 35.6 ± 19.8 40.1 ± 19.1 25.1 ± 17.9 0.01
ICU LOS (days) 22.0 ± 16.0 24.0 ± 16.5 17.4 ± 14.3 0.18
Hospital LOS prior to ICU (days) 7.9 ± 10.5 9.3 ± 11.5 4.4 ± 6.7 0.13
Time in ICU prior to candidemia  13.5 ± 13.2 16.9 ± 14.4 5.5 ± 3.8 0.004
Documented colonization (patients) 22 (44%) 18 (51%) 4 (27%) 0.13
Candida spp. patients (%)
  Albicans 14 (26%) 8 (23%) 6 (40%)
0.30
  Non-albicans 36 (74%) 27 (77%) 9 (60%)
Time to clearance (days) 8.6 ± 8.3 7.4 ± 7.9 9.0 ± 8.6 0.64
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colonization), whereas eighteen patients (51%) in the no-
shock group were colonized (eight patients urine, 10 sputum 
and 5 patients catheter-related). The difference did not reach 
statistical signiﬁ  cance (P = 0.135).
Table 3 shows odd ratios and conﬁ  dence intervals for 
shock development for the parameters identiﬁ  ed by univari-
ate analysis. Time in ICU before the development of candi-
demia reached signiﬁ  cance as predictor of shock develop-
ment. Area under the receiver operating curve was 0.826 
(Fig. 2). The threshold of < 7.2 days in ICU before the de-
velopment of candidemia allowed a discrimination between 
shock development and no shock with a sensitivity of 73.3% 
and a speciﬁ  city of 80.0%. A trend was also noted for hos-
pital and ICU LOS prior to development of candidemia, the 
lack of statistical signiﬁ  cance may be related to the limited 
sample size. Judging by the values of the Hosmer-Lemeshow 
and the likelihood ratio statistic, the model appears well cali-
brated.
Discussion
  
The present study shows that Candida induced septic shock 
is a nearly fatal condition with mortality rate that triples that 
of bacterial septic shock. Estimation of the true incidence of 
Candida induced septic shock is not possible from this study, 
although the percentage of patients with shock i.e. 30% in 
our ICU cohort is similar to the 27% and 23% frequency pre-
Table 3. Multiple Logistic Regression Analysis
Hosmer-Lemeshow statistic: 3.175 (P = 0.923); Likelihood ratio test statistic: 28.474 (P ≤ 0.001)
ICU: Intensive care unit; APACHE: Acute Physiology and Chronic Health Evaluation; LOS: Length 
of stay
Odds ratio 95% CI P Value
APACHE II score 1.007 0.882 - 1.149 0.919
Hospital LOS 0.902 0.805 - 1.010 0.075
ICU LOS 1.119 0.988 - 1.267 0.076
Hospital LOS before ICU 0.965 0.819 - 1.138 0.675
ICU LOS prior to candidemia 0.714 0.531 - 0.960 0.026
Candida colonization 0.291 0.037 - 2.258 0.237
Figure 2. Figure 2. Receiver operator curves for the three predictors with statistical signiﬁ  cance. Closed circles: 
ROC for time in ICU prior to candidemia; Open circles: ROC for ICU length of stay (LOS); Open diamonds: 
ROC for hospital LOS
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viously reported [15, 18]. The comparable rates strengthen 
the selection criteria employed to identify case patients in 
this retrospective cohort and highlight the high risk of pro-
gression to septic shock among critically ill patients who de-
velop candidemia, a fact ignored by many clinicians.
The high mortality observed among ICU patients with 
candidemia has been attributed to a number of factors, in-
cluding APACHE scores, inadequate initial ﬂ  uconazole dos-
ing, delayed administration of antifungal therapy due to slow 
fungal growth or insensitive culture methods, or retention 
of central venous catheters [12, 18]. High dose ﬂ  uconazole 
was the initial treatment in all but one patient. Although cur-
rent treatment guidelines suggest use of echinocandin agents 
or polyenes in hemodynamically unstable patient [19], these 
recommendations were published after the study occurred 
(1988 - 2003) and before the availability of echinocandins. It 
remains speculative whether the outcomes observed in this 
cohort have any relationship to the treatment provided. Nev-
ertheless, it is still feasible that the high mortality observed 
was a consequence of using a fungistatic agent such as ﬂ  uco-
nazole rather than fungicidal echinocandin or polyene agents. 
A more likely explanation is the time that our patients were 
without antifungal treatment awaiting blood cultures to turn 
positive. This emphasizes the need to introduce sensitive di-
agnostic assays that facilitate earlier pathogen identiﬁ  cation. 
Supporting this concept is the fact that almost a third of our 
patients died before isolating the organism responsible for 
septic shock and therefore did not receive antifungal treat-
ment. All patients were being treated with multiple antibiotic 
agents at the time of shock development, begging the ques-
tion whether clinicians should consider empiric antifungal 
therapy in patients who develop shock while receiving broad 
spectrum antimicrobial agents.
Although a number of studies have described risk fac-
tors for development of candidemia, none have speciﬁ  cally 
identiﬁ  ed factors predisposing to development of shock [13, 
14, 20, 21]. Using a multiple regression analysis we were 
able to identify the time spent in ICU until the development 
of candidemia as the only parameter that reached statistical 
signiﬁ  cance as shock predictor. ROC analysis suggests using 
a threshold of 7 days in the unit as the best way to identify 
who may develop shock due to candidemia. While this may 
be an important ﬁ  rst step alerting clinicians that there may 
be a higher chance for shock development in patients who 
develop candidemia early on the course of ICU stay, we real-
ize that the limited sample size precludes developing a more 
powerful model for better prediction of shock.
While not statistically signiﬁ  cant, proportionally more 
patients with C albicans developed shock. This observation 
was previously reported by Hadley et al, where 7 out of 10 
described episodes of candidemia and shock were caused by 
C. albicans [16]. Although it is tempting to postulate that 
inherent properties of each species would induce varying de-
grees of inﬂ  ammatory response and thus explain the higher 
incidence of shock observed by C. albicans, this hypothesis 
was not supported by Wisplinghoff et al [15]. The authors 
reported similar initial and most severe inﬂ  ammatory re-
sponses with both C albicans and non-albicans Candida spp. 
over time. The limited sample size precludes reaching any 
deﬁ  nitive conclusion, although these data may be hypoth-
esis generating and lead to further investigation to determine 
whether different species trigger different host response. Al-
though there has been a reported increase in the incidence of 
non-albicans Candida fungemia [6, 10], the observed ratio 
of non-albicans to C. albicans in our cohort is extremely 
high. It remains unknown whether this is a reﬂ  ection of an-
tibiotic and antifungal use within our medical center, or a 
reﬂ  ection of severity of disease in patients acquiring can-
didemia. Nonetheless, in selecting the initial early empiric 
antifungals one should recognize the high frequency of non-
albicans Candida species with intrinsic reduced ﬂ  uconazole 
susceptibility.
Our study has limitations. Because of its retrospective 
nature, the deﬁ  nition of shock induced by candidemia may 
be disputed, although we only included patients who had 
hypotension not explained by any other reason than infec-
tion and the percentage of patients progressing to shock is 
similar to previously described [15]. Similarly, colonization 
was not documented in all patients as it is not routine to do 
surveillance cultures for Candida in the US. The study pe-
riod preceded the introduction of echinocandins into clinical 
use. In spite of these limitations, this is to our knowledge one 
of the largest cohorts of patients with Candida induced septic 
shock and the ﬁ  rst that has attempted to identify predictors of 
shock development thus far.
In summary, septic shock due to candidemia in the 
ICU setting is associated with extremely high mortality. No 
conventional risk factors were identiﬁ  ed to predict shock 
development other than the time spent in ICU until the de-
velopment of candidemia. Given the high mortality associ-
ated with candidemic septic shock, consideration should be 
given for initiating empiric broad spectrum cidal antifungal 
therapy in high risk ICU patients already receiving and not 
responding to antibiotic therapy. This therapeutic approach 
should be validated by prospective studies.
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